The immune system recognizes many tumour’s as foreign. However, due to a multitude of factors, tumour cells may not be destroyed by immune cells, and therefore allowing a progression of the disease.
RORγt agonists have the potential to shift the balance from inhibitory cells called T-regs to immunity-promoting effector and cytotoxic T cells, and may provide the immune system with a novel tumour attacking mechanism. RORγt agonists have demonstrated single agent therapeutic activity in multiple animal models of cancer.
Nuevolution has identified potent RORγt agonists with the potential to offer a novel mode-of-action for treatment of cancer.